Another hypothesis supported by the results from a study on squamous cell carcinoma tumor cell lines is that antiPD-1 therapy induces the known cytotoxic T-cell activity and also a competitive TGFβ-driven immunosuppressive program, and therefore there is a benefit to be gained from using a TGF-β inhibitor [149]. This evidence concerns the gene TGFB1 and neoplasm.